Edition:
India

Deciphera Pharmaceuticals Inc (DCPH.OQ)

DCPH.OQ on NASDAQ Stock Exchange Global Select Market

24.23USD
20 Apr 2018
Change (% chg)

$0.09 (+0.37%)
Prev Close
$24.14
Open
$24.03
Day's High
$24.40
Day's Low
$23.71
Volume
25,906
Avg. Vol
60,632
52-wk High
$29.97
52-wk Low
$15.37

Chart for

About

Deciphera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing drugs to improve the lives of cancer patients. Its drug candidate includes DCC-2618, DCC-3014 and Rebastinib. Its proprietary kinase switch control inhibitor platform, inhibit the activation of kinases. DCC-2618, an orally... (more)

Overall

Beta: --
Market Cap(Mil.): $702.77
Shares Outstanding(Mil.): 30.68
Dividend: --
Yield (%): --

Financials

BRIEF-Deciphera Pharma Initiates Late Stage Study In Gastrointestinal Cancer Patients

* DECIPHERA PHARMACEUTICALS INITIATES PHASE 3 CLINICAL STUDY WITH DCC-2618 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMORS (“INVICTUS” STUDY)

04 Jan 2018

BRIEF-Deciphera Pharmaceuticals Announces Orphan Drug Designation From The EMA For DCC-2618 For The Treatment Of Gastrointestinal Stromal Tumors

* DECIPHERA PHARMACEUTICALS, INC. ANNOUNCES ORPHAN DRUG DESIGNATION FROM THE EMA FOR DCC-2618 FOR THE TREATMENT OF GASTROINTESTINAL STROMAL TUMORS Source text for Eikon: Further company coverage:

28 Nov 2017

BRIEF-Deciphera Pharma reports data from ongoing phase 1 clinical study of DCC-2618 

* Deciphera Pharmaceuticals reports data from ongoing phase 1 clinical study of DCC-2618 at the 22nd annual scientific meeting and education day of the society for neuro-oncology Source text for Eikon: Further company coverage:

20 Nov 2017

BRIEF-Deciphera Pharmaceuticals Q3 loss $5.85 per share​

* Deciphera Pharmaceuticals Inc announces third quarter 2017 financial results and corporate highlights

14 Nov 2017

Earnings vs. Estimates